Dr. Vijay Kumar Chopra

Senior Director

52 Years of Experience

Interventional Cardiologist

MBBS, DNB, DM, FACC, FESC, FSCAI, Fellowship

Reg. No.:4691, Haryana State Medical Council

Max Super Speciality Hospital, Saket, New Delhi

English, Hindi

Consultation Fee ₹ 1000

Book an Appointment

About Dr. Vijay Kumar Chopra

Dr. Vijay Kumar Chopra is a renowned Cardiologist with over 52 years of experience.
He has extensive expertise in cardiology, having worked in multiple cities across India.
The doctor specializes in preventive cardiology, clinical cardiology, heart failure, advanced heart diseases, ambulatory blood pressure monitoring, pulmonary function tests (PFT), and cardiac catheterization.
Dr. Vijay Kumar Chopra completed his MBBS from Christian Medical College, Vellore, in 1972 and a DNB in General Medicine from Postgraduate Institute of Medical Education and Research, Chandigarh, in 1976
In 1979, he obtained a DM in Cardiology from the Postgraduate Institute of Medical Education and Research, Chandigarh.
Later, he received an Invasive and Interventional Cardiology Fellowship from Fortis Escorts Heart Institute and Research Centre, New Delhi, and a Fellowship in Peripheral Vascular Interventions from Polyclinique Louis Pasteur, Nancy, France.
Dr. Chopra is a fellow of various prestigious international colleges and societies, such as the American College of Cardiology, the European Society of Cardiology, the Asia Pacific Society of Interventional Cardiology, and the Society of Angiography and Interventions.
He is actively involved in research and has published numerous papers. He has also participated in various workshops and conferences within the field of Cardiology.
The doctor is known for handling complex medical cases and providing accurate diagnoses with compassionate patient care.
Dr. Chopra is a member of the Cardiological Society of India.

Book Your Appointment With Dr. Vijay Kumar Chopra

Get a Treatment Plan Within 1 Hour

Name*

Mobile Number*

Is the above number on WhatsApp? *

Yes

Query

Education

MBBS, Christian Medical College and Hospital, Vellore, 1972
DNB (General Medicine), Postgraduate Institute of Medical Education and Research, Chandigarh, 1976
DM (Cardiology), Postgraduate Institute of Medical Education and Research, Chandigarh, 1979
Fellow of the American College of Cardiology (FACC), 2008
Fellow of the European Society of Cardiology (FESC)
Fellow of the Asia Pacific Society of Interventional Cardiology (FAPSIC)
Fellow of the Society of Angiography and Interventions (FSCAI)
Fellowship in Invasive and Interventional Cardiology, Fortis Escorts Heart Institute and Research Centre, New Delhi
Fellowship in Peripheral Vascular Interventions, Polyclinique Louis Pasteur, Nancy, France

Training & Certificates

Certificate of Honor in Medicine, Surgery, and Pathology, Christian Medical College, Vellore, 1972

Past Experience

Director (Heart Failure Program), Medanta – The Medicity, Gurgaon, 2019
Principal Consultant (Cardiology), Fortis Escorts Heart Institute and Research Centre, New Delhi, 2009
Senior Consultant (Cardiology), Ganga Ram Hospital, New Delhi, 2005
Senior Resident (Cardiology), Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, 1979

Awards

International Scholar, Cleveland Clinic, 1984
Kutumbiah Prize in Clinical Medicine, Christian Medical College, Vellore, 1972

Associations/Membership

Cardiological Society of India (CSI)

Paper Published

Dr. Vijay Kumar Chopra has published more than 60 articles in renowned national and international journals. Some of his work includes:

Rakisheva, Amina & Sliwa, Karen & Bauersachs, Johann & Van Linthout, Sophie & Chopra, Vijay & Bayes-Genis, Antoni & Fruzzetti, Franca & Cannata, Antonio & Deniau, Benjamin & Mebazaa, Alexandre & Savarese, Gianluigi & Ray, Robin & Vitale, Cristiana & Metra, Marco & Rosano, Giuseppe. (2024). Multidisciplinary care of peripartum heart failure: A scientific statement of the Heart Failure Association of the ESC. European journal of heart failure. 26. 10.1002/ejhf.3246.
Hernandez, Adrian & Udell, Jacob & Jones, W & Anker, Stefan & Petrie, Mark & Harrington, Josephine & Mattheus, Michaela & Seide, Svenja & Zwiener, Isabella & Amir, Offer & Bahit, M & Bauersachs, Johann & Bayes-Genis, Antoni & Chen, Yundai & Chopra, Vijay & Figtree, Gemma & Ge, Junbo & Goodman, Shaun & Gotcheva, Nina & Butler, Javed. (2024). Effect of Empagliflozin on Heart Failure Outcomes After Acute Myocardial Infarction: Insights from the EMPACT-MI Trial. Circulation. 149. 10.1161/CIRCULATIONAHA.124.069217.
Coats, Andrew & Butler, Javed & Tsutsui, Hiroyuki & Doehner, Wolfram & Filippatos, Gerasimos & Ferreira, Joao & Böhm, Michael & Chopra, Vijay & Verma, Subodh & Nordaby, Matias & Iwata, Tomoko & Nitta, Daisuke & Ponikowski, Piotr & Zannad, Faiez & Packer, Milton & Anker, Stefan. (2024). Efficacy of empagliflozin in heart failure with preserved ejection fraction according to frailty status in EMPEROR-Preserved. Journal of Cachexia, Sarcopenia and Muscle. 15. 10.1002/jcsm.13393.
Anker, Stefan & Usman, Muhammad & Anker, Markus & Butler, Javed & Böhm, Michael & Abraham, William & Adamo, Marianna & Chopra, Vijay & Cicoira, Mariantonietta & Cosentino, Francesco & Filippatos, Gerasimos & Lund, Lars & Moura, Brenda & Mullens, Wilfried & Pieske, Burkert & Ponikowski, Piotr & González-Juanatey, José & Savarese, Gianluigi & Seferovic, Petar & Rosano, Giuseppe. (2023). Patient Phenotype Profiling in Heart Failure with Preserved Ejection Fraction to Guide Therapeutic Decision Making A Scientific Statement of the Heart Failure Association (HFA) and the European Heart Rhythm Association (EHRA) of the ESC, and the European Society of Hypertension (ESH). European Journal of Heart Failure. 25. 10.1002/ejhf.2894.
Teramoto, Kanako & Tay, Wan Ting & Tromp, Jasper & Teng, Tiew-Hwa & Chandramouli, Chanchal & Ouwerkerk, Wouter & Lawson, Claire & Huang, Weiting & Hung, Chung-Lieh & Chopra, Vijay & Anand, Inder & Richards, Mark & Lam, Carolyn. (2022). Patient-Reported Versus Physician-Assessed Health Status in Heart Failure With Reduced and Preserved Ejection Fraction From ASIAN-HF Registry. Circulation. Cardiovascular quality and outcomes. 16. e009134. 10.1161/CIRCOUTCOMES.122.009134.
Anker, Stefan & Butler, Javed & Usman, Muhammad & Filippatos, Gerasimos & Ferreira, Joao & Bocchi, Edimar & Böhm, Michael & Brunner-La Rocca, Hans-Peter & Choi, Dong-Ju & Chopra, Vijay & Chuquiure, Eduardo & Giannetti, Nadia & Gomez-Mesa, Juan & Janssens, Stefan & Januzzi, James & González-Juanatey, José & Ph.D, Béla & Nicholls, Stephen & Perrone, Sergio & Zannad, Faiez. (2022). Efficacy of empagliflozin in heart failure with preserved versus mid-range ejection fraction: a pre-specified analysis of EMPEROR-Preserved. Nature Medicine. 28. 1-9. 10.1038/s41591-022-02041-5.
Teramoto, Kanako & Tay, Wan Ting & Tromp, Jasper & Teng, Tiew-Hwa & Chandramouli, Chanchal & Ouwerkerk, Wouter & Lawson, Claire & Huang, Weiting & Hung, Chung-Lieh & Chopra, Vijay & Anand, Inder & Richards, Mark & Lam, Carolyn. (2022). Patient Reported Versus Physician-Assessed Health Status in Heart Failure with Reduced and Preserved Ejection Fraction from Asian-Hf Registry. Journal of the American College of Cardiology. 79. 426. 10.1016/S0735-1097(22)01417-6.
Chopra, Vijay. (2022). Regional And Ethnic Influences on the Response to Empagliflozin in Patients With Heart Failure and A Preserved Ejection Fraction- Results from the Emperor-Preserved Trial. Journal of the American College of Cardiology. 79. 336. 10.1016/S0735-1097(22)01327-4.
Berg, David & Docherty, Kieran & Sattar, Naveed & Jarolim, Petr & Welsh, Paul & Jhund, Pardeep & Anand, Inder & Chopra, Vijay & de Boer, Rudolf & Kosiborod, Mikhail & Nicolau, José & O'Meara, Eileen & Schou, Morten & Hammarstedt, Ann & Langkilde, Anna-Maria & Lindholm, Daniel & Sjöstrand, Mikaela & Mcmurray, John & Sabatine, Marc & Morrow, David. (2021). Serial Assessment of High-Sensitivity Cardiac Troponin and the Effect of Dapagliflozin in Patients With Heart Failure With Reduced Ejection Fraction: An Analysis of the DAPA-HF Trial. Circulation. 145. 10.1161/CIRCULATIONAHA.121.057852.
Verma, Subodh & Dhingra, Nitish & Butler, Javed & Anker, Stefan & Ferreira, Joao & Filippatos, Gerasimos & Januzzi, James & Lam, Carolyn & Sattar, Naveed & Peil, Barbara & Nordaby, Matias & Pocock, Stuart & Zannad, Faiez & Packer, Milton & Packer, M & Anker, S & Butler, J & Filippatos, G. (2021). Empagliflozin in the treatment of heart failure with reduced ejection fraction in addition to background therapies and therapeutic combinations (EMPEROR-Reduced): a post-hoc analysis of a randomised, double-blind trial. The Lancet Diabetes & Endocrinology. 10. 10.1016/S2213-8587(21)00292-8.
Keech, Anthony & Oyama, Kazuma & Sever, Peter & Tang, Minao & Murphy, Sabina & Hirayama, Atsushi & Lu, Chen & Tay, Leslie & Deedwania, Prakash & Siu, David & Pineda, Armando & Choi, Donghoon & Charng, Min-Ji & Amerena, John & Ahmad, Wan & Chopra, Vijay & Pedersen, Terje & Giugliano, Robert & Sabatine, Marc. (2021). Efficacy and Safety of Long-Term Evolocumab Use Among Asian Subjects ? A Subgroup Analysis of the Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk (FOURIER) Trial ?. Circulation Journal. 85. 10.1253/circj.CJ-20-1051.
Kosiborod, Mikhail & Berwanger, Otavio & Koch, Gary & Martinez, Felipe & Mukhtar, Omar & Verma, Subodh & Chopra, Vijay & Javaheri, Ali & Ambery, Philip & Gasparyan, Boris & Buenconsejo, Joan & Sjöström, C. & Langkilde, Anna & Oscarsson, Jan & Esterline, Russell. (2020). Effects of Dapagliflozin on Prevention of Major Clinical Events and Recovery in Patients with Respiratory Failure due to COVID ?19: The Design and Rationale for the DARE?19 study. Diabetes, Obesity and Metabolism. 23. 10.1111/dom.14296.
Anker, Stefan & Butler, Javed & Khan, Muhammad & Abraham, William & Bauersachs, Johann & Bocchi, Edimar & Bozkurt, Biykem & Braunwald, Eugene & Chopra, Vijay & Cleland, John & Ezekowitz, Justin & Filippatos, Gerasimos & Friede, Tim & Hernandez, Adrian & Lam, Carolyn & Lindenfeld, Joann & Mcmurray, John & Mehra, Mandeep & Metra, Marco & Coats, Andrew. (2020). Conducting clinical trials in heart failure during (and after) the COVID-19 pandemic: An Expert Consensus Position Paper from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). European heart journal. 41. 10.1093/eurheartj/ehaa461.
Dewan, Pooja & Solomon, Scott & Jhund, Pardeep & Inzucchi, Silvio & Køber, Lars & Kosiborod, Mikhail & Martinez, Felipe & Ponikowski, Piotr & DeMets, David & Sabatine, Marc & Bengtsson, Olof & Sjöstrand, Mikaela & Langkilde, Anna & Anand, Inder & Belohlavek, Jan & Chopra, Vijay & Dukát, Andrej & Kitakaze, Masafumi & Merkely, Béla & Committees, DAPA?HF. (2020). Efficacy and safety of sodium–glucose co?transporter 2 inhibition according to left ventricular ejection fraction in DAPA?HF. European Journal of Heart Failure. 22. 10.1002/ejhf.1867.
Cunningham, Jonathan & Vaduganathan, Muthiah & Claggett, Brian & Zile, Michael & Anand, Inder & Packer, Milton & Zannad, Faiez & Lam, Carolyn & Janssens, Stefan & Jhund, Pardeep & Køber, Lars & Rouleau, Jean & Shah, Sanjiv & Chopra, Vijay & Shi, Victor & Lefkowitz, Martin & Prescott, Margaret & Pfeffer, Marc & Mcmurray, John & Solomon, Scott. (2020). Effects of Sacubitril/Valsartan on N-Terminal Pro-B-Type Natriuretic Peptide in Heart Failure With Preserved Ejection Fraction. JACC: Heart Failure. 8. 10.1016/j.jchf.2020.03.002.
Ray, Kausik & Colhoun, Helen & Szarek, Michael & Baccara-Dinet, Marie & Bhatt, Deepak & Bittner, Vera & Budaj, Andrzej & Díaz, Rafael & Goodman, Shaun & Hanotin, Corinne & Harrington, Robert & Jukema, Jw & Loizeau, Virginie & Lopes, Renato & Moryusef, Angele & Murin, Jan & Pordy, Robert & Ristic, Arsen & Roe, Matthew & McClanahan, Mark. (2019). Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial. The Lancet Diabetes & Endocrinology. 7. 10.1016/S2213-8587(19)30158-5.
Mcmurray, John & DeMets, David & Inzucchi, Silvio & Køber, Lars & Kosiborod, Mikhail & Langkilde, Anna & Martinez, Felipe & Bengtsson, Olof & Ponikowski, Piotr & Sabatine, Marc & Sjöstrand, Mikaela & Solomon, Scott & McMurray, John & Langkilde, Anna & Diez, Mirta & Nicolau, José & Katova, Tzvetana & O'Meara, Eileen & Ge, Junbo & Selvén, Mathilda. (2019). A trial to evaluate the effect of the sodium–glucose co?transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA?HF). European Journal of Heart Failure. 21. 10.1002/ejhf.1432.
Sharma, Abhinav & Lam, Carolyn & Tay, Wan Ting & Yap, Jonathan & MacDonald, Michael & Teng, Tiew-Hwa & Cooper, Lauren & Connor, Christopher & Whellan, David & Anand, Inder & Chopra, Vijay & Mentz, Robert. (2018). Causes of Death Among Patients with and without DIabetes and Chronic Heart Failure: Insights from the HF-ACTION and ASIAN-HF Registry. Journal of Cardiac Failure. 24. S69. 10.1016/j.cardfail.2018.07.292.
R, Bentley-Lewis & D, Aguilar & MC, Riddle & Claggett, Brian & R, Diaz & Dickstein, Kenneth & Gerstein, Hertzel & P, Johnston & Køber, Lars & F, Lawson & EF, Lewis & AP, Maggioni & JJ, McMurray & L, Ping & Probstfield, Jeffrey & Solomon, Scott & JC, Tardif & Y, Wu & MA, Pfeffer & Yuen, Kevin. (2015). Rationale, design, and baseline characteristics in Evaluation of LIXisenatide in Acute Coronary Syndrome, a long-term cardiovascular end point trial of lixisenatide versus placebo. American Heart Journal. 169(5):631-638.e7. 631-638.e7. 10.1016/j.ahj.2015.02.002..
Mcmurray, John & Packer, Milton & Desai, Akshay & Gong, Jim & Lefkowitz, Martin & Rizkala, Adel & Rouleau, Jean & Shi, Victor & Solomon, Scott & Swedberg, Karl & Zile, Michael & Martinez-Garcia, Francisco & Albisu, Juan Pablo & Alvarisqueta, Andres & Amuchastegui, M. & Astesiano, A. & Avila, Eros & Beloscar, J. & Berli, M. & Avendaño, A.. (2013). Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensin-converting enzyme inhibition in patients with chronic systolic heart failure: rationale for and design of the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF). European journal of heart failure. 15. 10.1093/eurjhf/hft052.
Passey, Rajiv & Talwar, Tisha & Jain, Rajneesh & Chopra, Vijay & Hussain, Shakir & Khanna, Purshottam. Left internal mammary artery to pulmonary vasculature fisulae closed with particle embolization: new forum of percatuneous intervention.